Wall Street analysts expect that Cerecor Inc (NASDAQ:CERC) will post ($0.16) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Cerecor’s earnings, with the highest EPS estimate coming in at ($0.14) and the lowest estimate coming in at ($0.18). Cerecor posted earnings per share of ($0.07) during the same quarter last year, which indicates a negative year-over-year growth rate of 128.6%. The company is expected to issue its next earnings results on Friday, May 10th.
On average, analysts expect that Cerecor will report full-year earnings of ($0.72) per share for the current year, with EPS estimates ranging from ($0.77) to ($0.69). For the next fiscal year, analysts expect that the firm will post earnings of ($0.76) per share, with EPS estimates ranging from ($0.83) to ($0.64). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Cerecor.
A number of research analysts have recently weighed in on the stock. Maxim Group assumed coverage on shares of Cerecor in a report on Tuesday, April 9th. They set a “buy” rating and a $10.00 price target on the stock. HC Wainwright assumed coverage on shares of Cerecor in a report on Monday, April 1st. They set a “buy” rating and a $11.00 price target on the stock. BidaskClub upgraded shares of Cerecor from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. ValuEngine downgraded shares of Cerecor from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 14th. Finally, TheStreet upgraded shares of Cerecor from a “d” rating to a “c-” rating in a report on Wednesday, January 30th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $10.00.
Shares of NASDAQ:CERC opened at $5.18 on Friday. The firm has a market cap of $220.52 million, a price-to-earnings ratio of 12.33 and a beta of 2.26. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.84 and a quick ratio of 0.79. Cerecor has a 12-month low of $2.71 and a 12-month high of $7.65.
In other news, major shareholder Armistice Capital Master Fund bought 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 27th. The shares were purchased at an average price of $5.47 per share, for a total transaction of $273,500.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Armistice Capital, Llc bought 13,762 shares of the company’s stock in a transaction that occurred on Monday, March 25th. The stock was purchased at an average price of $5.40 per share, for a total transaction of $74,314.80. The disclosure for this purchase can be found here. Insiders purchased a total of 577,734 shares of company stock worth $3,174,301 in the last quarter. Insiders own 80.20% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in CERC. Vanguard Group Inc raised its holdings in Cerecor by 10.1% in the 3rd quarter. Vanguard Group Inc now owns 87,929 shares of the company’s stock worth $411,000 after acquiring an additional 8,094 shares during the period. BlackRock Inc. raised its holdings in Cerecor by 18.5% in the 4th quarter. BlackRock Inc. now owns 33,960 shares of the company’s stock worth $109,000 after acquiring an additional 5,293 shares during the period. Northern Trust Corp raised its holdings in Cerecor by 47.9% in the 4th quarter. Northern Trust Corp now owns 20,079 shares of the company’s stock worth $65,000 after acquiring an additional 6,500 shares during the period. Geode Capital Management LLC raised its holdings in Cerecor by 50.7% in the 4th quarter. Geode Capital Management LLC now owns 94,990 shares of the company’s stock worth $306,000 after acquiring an additional 31,951 shares during the period. Finally, Prosight Management LP bought a new position in Cerecor in the 4th quarter worth $994,000. Hedge funds and other institutional investors own 50.26% of the company’s stock.
Cerecor Company Profile
Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Veripred, and Ulesfia for the treatment of inflammation of the skin, joints, lungs, and other organs, as well as asthma, allergies, arthritis, and head lice infestation.
See Also: What is a stock buyback?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.